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The discovery and development of novel anthelmintic classes is essential to sustain the control of so-
cioeconomically important parasitic worms of humans and animals. With the aim of offering novel, lead-
like scaffolds for drug discovery, Compounds Australia released the ‘Open Scaffolds’ collection containing
33,999 compounds, with extensive information available on the physicochemical properties of these
chemicals. In the present study, we screened 14,464 prioritised compounds from the ‘Open Scaffolds’
collection against the exsheathed third-stage larvae (xL3s) of Haemonchus contortus using recently
developed whole-organism screening assays. We identiﬁed a hit compound, called SN00797439, which
was shown to reproducibly reduce xL3 motility by  70%; this compound induced a characteristic,
“coiled” xL3 phenotype (IC50 ¼ 3.46e5.93 mM), inhibited motility of fourth-stage larvae (L4s; IC50 ¼ 0.31
e12.5 mM) and caused considerable cuticular damage to L4s in vitro. When tested on other parasitic
nematodes in vitro, SN00797439 was shown to inhibit (IC50 ¼ 3e50 mM) adults of Ancylostoma ceyla-
nicum (hookworm) and ﬁrst-stage larvae of Trichuris muris (whipworm) and eventually kill (>90%) these
stages. Furthermore, this compound completely inhibited the motility of female and male adults of
Brugia malayi (50e100 mM) as well as microﬁlariae of both B. malayi and Diroﬁlaria immitis (heartworm).
Overall, these results show that SN00797439 acts against genetically (evolutionarily) distant parasitic
nematodes i.e. H. contortus and A. ceylanicum [strongyloids] vs. B. malayi and D. immitis [ﬁlarioids] vs. T.
muris [enoplid], and, thus, might offer a novel, lead-like scaffold for the development of a relatively
broad-spectrum anthelmintic. Our future work will focus on assessing the activity of SN00797439 against
other pathogens that cause neglected tropical diseases, optimising analogs with improved biological
activities and characterising their targets.
© 2017 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).* In appreciation of the efforts of David Camp, Graeme Stevenson, Mikhail Krasavin, Alain-Dominique Gorse and other colleagues for originally assembling and maintaining
the 'Open Scaffolds' collection.bar), robinbg@unimelb.edu.au (R.B. Gasser).
Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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Parasitic worms (helminths) of animals and humans cause
chronic and often deadly diseases that have a major socioeconomic
impact worldwide (Fenwick, 2012; Fitzpatrick, 2013). On one hand,
in humans, the disease burden due to parasitic worms represents
~14 million disability-adjusted life years (DALYs) globally, repre-
senting half of the DALYs caused by major neglected tropical dis-
eases (Hotez et al., 2014, 2016). On the other hand, in agricultural
animals, the annual economic losses due to death, poor health and
reduced productivity caused by parasitic worms are estimated at
billions of dollars per annum worldwide (cf. Knox et al., 2012;
Roeber et al., 2013). In Australia alone, worms of cattle and sheep
cause economic losses estimated at 500 million dollars per annum
(Lane et al., 2015). As no vaccines are available for the vast majority
of these parasites, their control relies predominantly on the use of
(usually) one of a small number of medicines (anthelmintics). These
anthelmintics are only, at best, partially effective, and their exces-
sive and widespread use, particularly in livestock animals, has led
to serious drug resistance problems around the world (Kaplan and
Vidyashankar, 2012; Wolstenholme and Kaplan, 2012; Kotze and
Prichard, 2016). Therefore, the ongoing development of novel
treatments is crucial for the control of parasitic worms of animals.
Despite some success through the discovery of, for example,
monepantel (Kaminsky et al., 2008; Prichard and Geary, 2008) and
derquantel (Little et al., 2011), there has been relatively limited
progress in discovering and developing new drugs against parasitic
roundworms (nematodes), because of major challenges associated
with development and translation to the market (Geary et al.,
2015). Major hurdles include achieving anthelmintic efﬁcacy with
an acceptable therapeutic index, the ability to develop formulations
that deliver the pharmacokinetic proﬁle necessary for efﬁcacy,
while maintaining the therapeutic index to support safety, as well
as achieving human food safety requirements linked to the use of
food animal products and a low cost of manufacturing the drugs (cf.
Geary et al., 2015; Campbell, 2016).
In 2008, the Queensland Compound Library (QCL), now called
Compounds Australia, established a dedicated compound manage-
ment facility to augment capability in chemical screening and
biomedical research, including the discovery of new anti-parasite
drugs (Simpson and Poulsen, 2014). A key role of Compounds
Australia has been to source small molecules, to consolidate them
into a central repository that facilitates subsequent screening and
to provide these molecules to laboratories around the world to
support drug discovery efforts.
Currently, Compounds Australia maintains three main collec-
tions: ‘Open Scaffolds’ (with ~33,400 compounds), ‘Open Academic’
(~19,500) and ‘Open Drugs’ (~2500; Food and Drug Administration
[FDA]-approved) (Simpson and Poulsen, 2014). Each collection is
well curated and characterized, with extensive information avail-
able on the physicochemical properties of compounds, including
“rule-of-ﬁve” descriptors (chirality, hydrogen bonding acceptor and
donors, logP and molecular weight), and chemical ﬁngerprints. The
ready availability of these resources provided us with a unique
opportunity to evaluate selected compound groups for activity
against parasitic nematodes using recently developed whole-
organism screening assays. Therefore, we elected to screen priori-
tised compounds from the largest library, ‘Open Scaffolds’, against
parasitic stages of the barber's pole worm, Haemonchus contortus
(of ruminants), to identify hit compounds, and then characterise
and assess them as nematocidal candidates.2. Materials and methods
2.1. The compound library, and the selection and preparation of
chemicals for screening
We purchased a prioritised set of compounds from the ‘Open
Scaffolds’ collection from Compounds Australia, which contains a
total of 33,999 chemicals representing 1226 scaffolds (Simpson and
Poulsen, 2014). This collection contains novel, lead-like scaffolds
(or chemotypes), with an average of 28 compounds per scaffold to
allow meaningful structure-activity relationships (SAR) to be
explored. For each compound, the simpliﬁed molecular-input line-
entry system (SMILES) string was converted to SYBYL line notation
(SLN; Homer et al., 2008) using SYBL software (www.certara.com/
software/molecular-modeling-and-simulation/sybyl-x-suite/); us-
ing this approach, 33,949 compounds were annotated. Then, we
selected a subset of representative compounds from this library
using the following steps. First, we removed 213 pan assay inter-
ference compounds (PAINs) (Baell and Holloway, 2010, Baell, 2016).
Second, we subjected the remaining chemicals to stringent physi-
cochemical and structural ﬁltering, in order to select compounds
with the highest probability of permeating cells, being soluble and
being chemically optimised as drugs, using the following criteria:
mixtures, metals, isotopes: 0, minimum number of rings: 1,
maximum number of rings: 4; minimum molecular weight:
150 kDa; maximum molecular weight: 400 kDa; hydrogen bond
donors:  3; hydrogen bond acceptors:  6; minimum number of
hydrogen bond acceptors: 1; maximum number of chiral centers:
3; maximum number of rotatable bonds: 10; this process removed
14,328 compounds, leaving 19,408 compounds. Third, compounds
that were > 90% similar to each other in structure were removed,
leaving a ﬁnal set of 14,464 compounds. These 14,464 compounds
(Supplementary File 1) were individually solubilised in dimethyl
sulfoxide (DMSO; cat no. 2225; Ajax Finechem, Australia) to ach-
ieve a stock concentration of 5 mM, and then diluted and tested for
activity against H. contortus (see Subsection 2.2).2.2. Screening and evaluation of the effects of compounds on
H. contortus
2.2.1. Production of parasitic larvae
Haemonchus contortus (Haecon-5 strain) was maintained in
experimental sheep in accordance with institutional animal ethics
guidelines (permit no. 1413429; The University of Melbourne) as
described previously (Preston et al., 2015). To produce exsheathed
third-stage larvae (xL3s), L3s were exposed to 0.15% (v/v) of sodium
hypochlorite (NaClO) for 20 min at 37 C (Preston et al., 2015),
washed ﬁve times in sterile saline (0.9%) and cultured in Luria
Bertani medium (LB) and supplemented with ﬁnal concentrations
of 100 IU/ml of penicillin, 100 mg/ml of streptomycin and 2 mg/ml of
amphotericin (antibiotic-antimycotic, cat. no. 15240-062; Gibco,
Life Technologies, USA) (LB*). To produce fourth-stage larvae (L4s),
xL3s were incubated in a water-jacketed CO2 incubator (model no.
2406 Shel Lab, USA) for 7 days at 38 C and 10% v/v CO2 or until
 80% of L3s had developed to the L4 stage.2.2.2. Preparation of compounds for screening
Compounds were supplied from Compounds Australia at a con-
centration of 5mM. Individual compoundswere diluted to 40 mM in
LB* containing 1% DMSO and dispensed in 50 ml into the wells of
sterile 96-well ﬂat bottommicroplates (cat no. 3635; Corning 3650,
Life Sciences, USA) using an automated, multi-channel pipetting
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and LB* were both included as negative controls in screening as-
says. The anthelmintics moxidectin (Cydectin®, Virbac, France) and
monepantel (Zolvix®, Novartis Animal Health, Switzerland) were
used as positive-control compounds in screening assays.
2.2.3. Screening of compounds for their effect on xL3 motility
Thewhole-organism screening assay developed by Preston et al.
(2016a) was used to evaluate the effect of compounds on the
motility of xL3s of H. contortus. On each 96-well plate, the positive-
control compounds (moxidectin and/or monepantel) were arrayed
in triplicate. Six wells were used for each negative control (LB*þ 1%
DMSO and LB* alone). Test compounds were arrayed in individual
wells. Following dispensing into the plates, 300 xL3s in 50 ml of LB*
were transferred to each well of each plate (with the exception of
perimeter wells) using a multi-channel pipette (Finnpipette,
Thermo Scientiﬁc). During dispensing, xL3s were kept in a ho-
mogenous suspension by bubbling air through the solution using
an air pump (Airpump-S100; Aquatrade, Australia). Thus, following
the addition of xL3s to individual wells, the ﬁnal concentrations
were 20 mM (compound) and 0.5% (DMSO).
Plateswere incubated in awater-jacketed CO2 incubator at 38 C
and 10% v/v CO2. After 72 h, the plates were agitated (126 rotations
per min) using an orbital shaker (model EOM5, Ratek, Australia) for
20 min at 38 C. In order to capture the motility of xL3s at 72 h, a
video recording (5 sec) was taken of each well on each plate as
described previously (Preston et al., 2016a). Each 5 sec-video cap-
ture of each well was processed using a custom macro in the pro-
gram Image J (1.47v, imagej.nih.gov/ij), which indirectly measured
larval motility by quantifying the changes in light intensity over
time (cf. Preston et al., 2016a).
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.ijpddr.2017.05.004.
2.2.4. Screening of compounds for their effect on the motility and
development/growth of fourth-stage larvae (L4s)
The motility of L4s was evaluated using the same protocol as for
xL3 (see Subsection 2.2.3; Preston et al., 2016a). Following the
measurement of larval motility, plates were re-incubated for four
more days in a humidiﬁed environment (water-jacketed CO2
incubator) at 38 C and 10% v/v CO2. Then, worms were ﬁxed with
50 ml of 1% iodine, and 30 worms from each well were examined at
20-times magniﬁcation (DP26 camera, Olympus, Japan) to assess
their development based on the presence of a well-developed
mouth/pharynx in H. contortus L4s (see Sommerville, 1966). The
number of L4s was expressed as a percentage of the total worm
number (n ¼ 30). Compounds were tested in triplicate on three
different days.
2.2.5. Analyses of results from bioassays using H. contortus
Raw data were normalised against values of the positive and
negative controls to remove plate-to-plate variation by calculating
the percentage of motility using the program GraphPad Prism (v.6
GraphPad Software, USA). A compound was recorded as having
anti-xL3 activity if it reduced motility by 70% at 72 h, and was re-
screened at 20 mM to conﬁrm its inhibitory properties on motility.
For a compound that consistently reduced xL3 motility
by  70%, an 18-point dose-response curve (two-fold serial di-
lutions; from 100 mM to 0.00076 mM) was produced for xL3 and L4,
to establish its half maximal inhibitory concentration (IC50). For xL3
and L4, motility was measured at 24 h, 48 h and 72 h, and L4
development at 7 days of incubation with each active compound
(triplicate) (Subsection 2.2.3). Compound concentrations were
transformed using the equation (x ¼ log10 (concentration in nM))
and a log (agonist) versus response – variable slope (fourparameter) equation, in GraphPad prism v.6.07 was used to calcu-
late IC50 values. For L4 development, IC50 values were calculated
using the same approach. If a IC50 value could not be accurately
calculated by the log (agonist) versus response – variable slope (four
parameter) equation, a range for the IC50 value was given.
2.3. Scanning electron microscopy
This microscopy technique was used to assess whether com-
pounds that reducedmotility by 70% caused structural damage to
the larval stages of H. contortus, as described previously (Preston
et al., 2016b). The xL3s and L4s were produced and cultured as
described previously (Preston et al., 2015; Subsections 2.2.1e2.2.2).
Six replicates of 300 xL3s or L4s were incubated in 100 mM of each
compound in LB* for 24 h at 38 C and 10% v/v CO2. Larvae were
pooled, washed 3 times in 0.9% saline at 9000  g and resuspended
in 1ml of phosphate-buffered saline (PBS). Subsequently, the larvae
were ﬁxed and processed as described previously (Preston et al.,
2016b). Larvae were imaged using a ﬁeld-emission scanning elec-
tron microscope (XL30 Philips, Netherlands); six representative
images were taken of each sample.
2.4. Evaluating compound activity on ﬁlarial worms
2.4.1. Procurement of ﬁlarial nematodes
The Filariasis Research Reagent Resource Center (Athens, Geor-
gia, USA; http://www.ﬁlariasiscenter.org/) has ofﬁcial ethics
approval to produce ﬁlarial nematodes in experimental animals.
From this centre, we obtained fresh, live adults of Brugia malayi,
produced in Meriones unguiculatus (jird) (Michalski et al., 2011;
Mutafchiev et al., 2014). Fresh, live microﬁlariae of Diroﬁlaria immi-
tis (Missouri strain) obtained from the bloods from dogs with patent
infection (cf. Michalski et al., 2011; Mutafchiev et al., 2014) were
maintained in RPMI-1640 medium (Gibco, Life Technologies, USA).
2.4.2. Assessing compound activity against adults and microﬁlariae
of B. malayi
A compound with known activity against H. contortus was
purchased from ChemDiv (USA) and then dissolved in DMSO to
reach a stock concentration of 30 mM, and then tested for its effect
on the motility of adult female and male B. malayi (see Storey et al.,
2014). First, adults were manually separated from each other with
forceps, and individuals transferred to single wells of 24-well plates
containing 500 ml of RPMI-1640 (Gibco, Life Technologies, USA)
supplemented with 10 mg/ml of gentamycin and 2.5 mg/ml
amphotericin B (designated RPMI*) at 37 C. Two-fold dilutions
(100 mMe0.97 mM) of each compound in 500 ml of RPMI* were
tested in duplicate (adding the same volume to the wells). RPMI*
plus 1% DMSO, but without compound, was added to four negative-
control wells. The plates were then incubated at 37 C and 5% v/v
CO2. Subsequently, using the Worminator image analysis system
(Storey et al., 2014), the motility of individual adult worms was
recorded after 24 h and 48 h of incubation. In brief, at each time
point, a video recording (1 min) was taken of each well on each
plate until the standard deviation reached zero.
In addition, the effect of compounds on the production and
motility of microﬁlariae originating from individual gravid females
of B. malayi after 72 h of incubation was assessed. To do this, 200 ml
of medium (RPMI* plus 1% DMSO) containing ~100 microﬁlariae
from individual wells were transferred to individual wells of a 96-
well plate and recorded for 30 sec (in the same manner as for adult
worms) using theWorminator. All assays were repeated thrice, and
IC50 values were calculated using the log (agonist) versus response –
variable slope (four parameter) equation – in GraphPad Prism (v.6
GraphPad Software).
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immitis
To assess the effects on the microﬁlariae of D. immitis, com-
pounds were serially diluted two-fold (100 mMe0.39 mM) in 96-
well plates; RPMI* was used as the medium, and each compound
dilution was tested in triplicate. Six wells contained RPMI* plus 1%
DMSO (negative controls). In test wells, 50 ml of RPMI* containing
~100 microﬁlariae were added to each well using a multi-channel
pipette. Plates were then incubated at 37 C and 5% v/v CO2. At
24 h and 48 h, plates were imaged for microﬁlarial motility using
the Worminator (see Subsection 2.4.2). All assays were repeated
thrice on different days, and IC50 values were determined using
GraphPad prism (Subsection 2.2.5).
2.5. Assessing compound activity on adult A. ceylanicum and
T. muris L1s
Adults of A. ceylanicum were collected from the small intestine
of hamsters, which had been infected orally with 150 A. ceylanicum
L3s for three weeks. For each compound, three worms were placed
in each well of a 24-well plate, using 2 wells per compound. Le-
vamisole (50 mM)was used as a positive-control compound.Worms
were incubated in the presence of 50 mM of each compound, and
culture medium, which was composed of Hanks' Balanced Salt
Solution (HBSS) supplemented with 10% foetal calf serum, 25 mg/ml
of amphotericin B, 100 U/ml of penicillin and 100 mg/ml of strep-
tomycin. Worms were kept in an incubator at 37 C and 5% v/v CO2
for 72 h. Thereafter, the condition of the worms was microscopi-
cally evaluated.
For T. muris, 40 L1s were placed in each well of a 96-well plate
and incubated for 24 h at 37 C and 5% v/v CO2 in the presence of
100 ml RPMI-1640 medium with amphotericin B (12.5 mg/ml),
penicillin (500 U/ml), streptomycin (500 mg/ml) and 100 mM of the
compound to be tested. Levamisole (100 mM) was used as a
positive-control compound. Each compound was tested in dupli-
cate. At 24 h, the total number of L1s per well was counted. The
larvae were then stimulated with 100 ml hot water and motile L1s
were counted.
2.6. Assessing compound cytotoxicity and selectivity
Cell toxicity was assessed in a mammary epithelial cell line
(MCF10A), essentially as described previously (Kumarasingha et al.,
2016). In brief, MCF10A cells were seeded in black walled, ﬂat
bottom 384 well black walled plates (Corning, USA) at 700 cells/
well using a BioTek 406 automated liquid handling dispenser
(BioTek, Vermont, USA) in a total volume of 40 ml/well. Cells were
cultured in DMEM-F12 containing 5% horse serum (Life Technolo-
gies, Australia), 20 ng/ml human epidermal growth factor (EGF, Life
Technologies, Australia), 100 ng/ml cholera toxin (Sigma, Australia),
0.5 mg/ml hydrocortisone (Sigma, Australia) and 10 mg/ml insulin
(human; Novo Nordisk Pharmaceuticals Pty Ltd, Australia). After an
incubation for 24 h at 37 C, 5% v/v CO2, the growth medium was
aspirated and the cells were treated with test compounds, starting
at 100 mM, and positive and negative controls (media ±1% DMSO,
monepantel, moxidectin). The chemotherapeutic compound doxo-
rubicin, starting at 10 mM, was also used as a positive control.
Compounds were titrated to generate a ﬁve-point dose-response
curve, in quadruplicate, using an automated liquid handling robot
(SciClone ALH3000 Lab Automation Liquid Handler, Caliper Life-
sciences, USA) and incubated for a further 48 h. Matched DMSO
concentrations for each compound concentration were also tested
separately to account for DMSO induced cell toxicity. To measure
cell proliferation, cells were ﬁxed and stained with 40,6-diamidino-
2-phenylindole (DAPI; 1:1000), and individual wells imaged at 10-times magniﬁcation, covering 16 ﬁelds (~90% of well) using a high
content imager (Cellomics CellInsight Personal Cell Imager, Ther-
moFisher Scientiﬁc, USA) at a ﬁxed exposure time of 0.12 sec. Viable
cells were counted using the Target Activation BioApplication
within the Cellomics Scan software (v.6.5.0, Thermo Scientiﬁc, USA)
and normalised to the cell density in wells without compound.
Toxicity due to DMSO was removed from the normalised cell
density counts and IC50 values calculated from the variable slope
four-parameter equation (v.6 GraphPad Software). Experiments
were repeated twice on two different days using four technical
replicates for each compound.
3. Results and discussion
3.1. The identiﬁcation of compound SN00797439 with activity
against parasitic stages of H. contortus
In the primary screen, we tested all 14,464 prioritised com-
pounds from the ‘Open Scaffolds’ collection against H. contortus
xL3s (Fig. 1A). Any compounds that consistently reduced xL3
motility (in independent screens) by > 70% at 72 h was recorded as
a “hit” (Fig. 1B). Of all compounds tested, a chemical, designated
SN00797439 (IUPAC name: N-(4-chlorophenyl)-2-(3-phenyl-1,2,4-
oxadiazol-5-yl)-1-pyrrolidinecarboxamide) reduced xL3 motility
by 70% in both the primary and subsequent conﬁrmatory screens
(Fig. 1B); this compound caused a “coiled” xL3 phenotype (Sup-
plementary File 2). The chemical structure and predicted physico-
chemical properties of SN00797439 are given in Fig. 1.
Dose-response curves (two-fold serial dilutions from 100 mM to
0.00076 mM) showed that SN00797439 inhibited xL3 motility, with
IC50 values of 3.46 ± 0.82 mM (24 h), 10.08 ± 2.06 mM (48 h), and
5.93 ± 1.38 mM (72 h) (Fig. 2; Table 1); these IC50 values were
comparable with those of monepantel and moxidectin (positive-
control compounds).
Dose-response curves (two-fold serial dilutions from 100 mM to
0.00076 mM) revealed that SN00797439 inhibited the motility of
L4s, with IC50 values of 6.25e12.5 mM (24 h), 0.78e1.5 mM (48 h)
and 0.31e0.78 mM (72 h) (Fig. 2; Table 1). Subsequently,
SN00797439 was tested for its ability to inhibit growth/develop-
ment from xL3 to L4. The dose-response curves revealed that this
compound inhibited L4 development, with an IC50 value of
11.04 ± 2.16 mM (Fig. 2; Table 1). Upon SEM analysis, SN00797439
caused only minor morphological damage to xL3, but resulted in
considerable cuticle alterations to the L4 stage, including multiple,
cuticle-‘embossed’ rings around the worm along its length and a
‘scaly’ appearance of the worm surface (Fig. 3).
3.2. Compound SN00797439 also has inhibitory activity on the
motility of different developmental stages of other parasitic
nematodes
In order to assess whether compound SN00797439 would act
against nematodes that are genetically (evolutionarily) very distant
from H. contortus (order Strongylida), we tested whether these
compounds would inhibit the motility of adults andmicroﬁlariae of
B. malayi as well as microﬁlariae of D. immitis in vitro. SN00797439
inhibited the motility of female and male adults of B. malayi (Fig. 4;
Table 2), with movement ceasing at 100 mM (24 h) and 50 mM
(48 h). This result compares with 1.3 mM (24 h) and 2.9 mM (48 h)
for moxidectin (cf. Storey et al., 2014). SN00797439 was then tested
for its effect on microﬁlariae of B. malayi (released from females
after 72 h in vitro), and inhibited the motility of the microﬁlariae,
with an IC50 of ~3 mM (24 h) compared with ~6 mM for moxidectin
(cf. Storey et al., 2014).
Subsequently, SN00797439 was tested against microﬁlariae of
Fig. 1. Panel A: Three-dimensional scatterplot displaying the physicochemical properties of molecular weights (in g mol1), calculated partition coefﬁcients (LogP) and topological
polar surface areas (in Å2) of all 14,464 compounds prioritised from 33,999 compounds contained within the ‘Open Scaffolds’ collection. Panel B: Primary screen of the 14,464
compounds at the concentration of 20 mM identiﬁed compound SN00797439 to inhibit the motility of exsheathed third-stage larvae (xL3) by  70% compared with negative
(LB* þ 0.5% dimethyl sulfoxide; DMSO) and positive controls (monepantel and moxidectin). The chemical structure and predicted physicochemical properties of SN00797439 are
listed at the bottom of the image.
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inhibited the motility of microﬁlariae, with complete inhibition at
100 mM (24 h and 48 h). For both of these time points, an IC50 value
of ~50 mMwas achieved (Table 2), which compares with IC50 values
of 43 mM and 9.3 mM published for ivermectin and moxidectin,
respectively (Storey et al., 2014). In addition, when tested on
A. ceylanicum and T. muris, SN00797439 killed adult A. ceylanicum at
50 mM and displayed a high nematocidal activity against T. muris
L1s (90.1% of L1s dead at 100 mM). The positive-control compound
(levamisole) killed both nematode species at the sameconcentration as used for the test compound. Further work should
be conducted to assess the activity of SN00797439 against late
larval stages and adults of both D. immitis and T. muris.
3.3. Cytotoxicity and selectivity of SN00797439
Using an established proliferation assay, SN00797439 was
assessed for its toxicity on mammary epithelial cells (Table 3) and
was shown to be selective for parasitic larvae of H. contortus, with a
selectivity index (SI) of ~9e128, compared with ~67e332
Fig. 2. Dose-response curves for compounds SN00797439 on larval stages of Haemonchus contortus in vitro with reference to the positive-control compounds monepantel and
moxidectin. Inhibition of the motility of third-stage larvae (xL3s) at 24 h, 48 h and 72 h as well as fourth-stage larvae (L4s) at 24 h, 48 h and 72 h for individual compounds (A); and
the inhibition of the development of L4s after seven days in vitro culture (B). Each data point represents the mean of three experiments repeated in triplicate on separate days
(± standard error of the mean, SEM).
Table 1
Testing of the effects of the active compound SN00797439 from the Compounds Australia ‘Open Scaffolds’ collection on the motility of exsheathed
third-stage larvae (xL3s) as well as the motility and development of fourth-stage larvae (L4s) of Haemonchus contortus. A comparison of ‘half of the
maximum inhibitory concentration’ (IC50) values with those of reference anthelmintic compounds (monepantel and moxidectin); expressed as
mean IC50 (in mM) ± standard error of the mean or a range.
Time point SN00797439 Monepantel Moxidectin
xL3 motility
24 h 3.46 ± 0.82 0.48 ± 0.23 0.19 ± 0.03
48 h 10.08 ± 2.06 0.26 ± 0.15 0.97 ± 0.84
72 h 5.93 ± 1.38 0.16 ± 0.08 0.08 ± 0.04
L4 motility
24 h 6.25 to 12.5 0.76 ± 0.29 0.07 ± 0.04
48 h 0.78 to 1.5 0.34 ± 0.18 0.05 ± 0.02
72 h 0.31 to 0.78 0.37 ± 0.32 0.02 ± 0.01
L4 development
7 days 11.04 ± 2.16 0.075 ± 0.04 3.45 ± 0.75
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Fig. 3. Scanning electron microscopic images of exsheathed third-stage larvae (xL3) and fourth-stage (L4) larvae of Haemonchus contortus following exposure to 100 mM of
compound SN00797439, monepantel (positive control) or LB* þ 1% DMSO (negative control). Arrows indicate the cuticular alterations observed following treatment with
SN00797439. Scale ¼ 20 mM.
Fig. 4. The inhibitory effect of compound SN00797439 from the Open Scaffolds collection on the motility of female and male adult Brugia malayi at 24 h (panels A and B). The
inhibitory effect of compound SN00797439 (C) on Diroﬁlaria immitismicroﬁlariae (mff) at 24 h and 48 h. Dose-response experiments were performed at 100 mM and serially diluted
two-fold. Each data point represents the mean of at least two experiments repeated in duplicate on separate days (± standard error of the mean, SEM).
Table 2
Testing the effect of compound SN00797439 from the Open Scaffolds collection on the motility of ﬁlarial nematodes Brugia malayi and
Diroﬁlaria immitis. Approximate ‘half of the maximum inhibitory concentration’ (IC50) values of individual compounds are indicated.
Time point Parasite/stage/sex SN00797439
IC50 (mM)
Brugia malayi
24 h Adult female 25 to 50
24 h Adult male 25 to 50
72 h Microﬁlariae 3
Diroﬁlaria immits
24 h Microﬁlariae 50
48 h Microﬁlariae 50
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Table 3
Cytotoxicity of compound SN00797439 on a normal mammary epithelial cell line (MCF10A) and selectivity of these compounds on Haemonchus contortus exsheathed third-
stage larvae (xL3) and fourth-stage larvae (L4), Diroﬁlaria immitis microﬁlariae (mff) and Brugia malayi mff and adult ﬁlarial worms. Selectivity indices (SIs) were calculated
using a recognised formula; (SI ¼ ‘half of the maximum inhibitory concentration’ (IC50) for MCF10A cells/IC50 for nematode).
Compound MCF10A cells Selectivity index (SI)a
H. contortus Filarioids
IC50 (mM) % inhibition at 100 mMc xL3
(72 h)
L4
development (7 days)
L4 (72 h) B. malayi adult
females
B. malayi adult
males
B. malayi
mff
D. immitis
mff
(48 h)
SN00797439 50e100 6.20 ± 0.66 16.9 9.1 128.2b 2b 2b 33.33b 2b
Monepantel 24.93 ± 11.83 0.10 ± 0.05 115.8 332.4 67.4 n.d. n.d. n.d. n.d.
Moxidectin <6 0.05 ± 0.01 75 1.7 300 n.d. n.d. n.d. n.d.
n.d. ¼ not determined.
a Selectivity indices were calculated based on the highest value in the IC50 range.
b Selectivity indices were calculated based on the estimated IC50 range from Tables 1 and 2.
c Expressed as mean ± standard deviation.
S. Preston et al. / International Journal for Parasitology: Drugs and Drug Resistance 7 (2017) 286e294 293(monepantel) and ~2 to 300 (moxidectin) for the positive-control
compounds (Table 3). For ﬁlarial worms, SN00797439 was selec-
tive only for microﬁlariae of B. malayi (but not D. immitis) with an SI
of 33.3.4. Conclusion
In the past three decades, only four ‘new’ anthelmintic drugs,
emodepside (Martin et al., 2012; Harder, 2016), tribendimidine
(Xiao et al., 2005; Steinmann et al., 2008), monepantel (Kaminsky
et al., 2008; Prichard and Geary, 2008) and derquantel (Little
et al., 2011), have been commercialised. Due to the rapid emer-
gence of anthelmintic resistance, even to some recently commer-
cialised compounds (Scott et al., 2013; Van den Brom et al., 2015;
Sales and Love, 2016; Cintra et al., 2016), there is a need to iden-
tify, validate, optimise and develop novel chemical entities for the
treatment of parasitic worms of humans and agricultural animals
(Geary et al., 2015).
With this focus in mind, we screened 14,464 prioritised com-
pounds (representing a collection of 33,999 chemicals) to identify
potential starting points for the design of new anthelmintics. Under
the conditions used in this screening platform, compound
SN00797439 was identiﬁed as a hit, and exhibited considerable
anthelmintic activity against H. contortus and induced a “coiled”
phenotype (Supplementary File 2). SN00797439 was also shown to
have anthelmintic activity against a species of hookworm
(A. ceylanicum; order Strongylida) and two ﬁlarioid nematodes
(D. immitis and B. malayi; order Spirurida). Additionally, this com-
pound was also shown to have activity against the mouse whip-
worm, T. muris, which is used as a model to study the genetically
related human whipworm (T. trichiura; order Enoplida) (cf. Foth
et al., 2014) These ﬁndings, for multiple representatives of taxo-
nomically, biologically and genetically distinct orders (i.e. Strong-
ylida vs. Spirurida vs. Enoplida), indicate a relatively broad
spectrum of in vitro activity of this chemotype against nematodes.
Compound SN00797439 is made up of an oxadiazole and pyr-
rolidine core. An appraisal of the intellectual property surrounding
the sub-structures of this compound (Li and Zhong, 2011, 2010)
reveals that similar compounds have been explored as therapeutics
for the control of hepatitis C, but not yet as anthelmintics. Following
the identiﬁcation of SN00797439 in the primary screen against
H. contortus, an evaluation revealed differences in its potency to
inhibit the motility, growth and/or development of the parasitic
larval stages of this nematode. The results showed that
SN00797439 was more potent on L4s than xL3s. This difference in
potency might be due to variation in expression of its target(s) in
the nematode, a distinction in physiology between these two
developmental stages of the worm and/or the nature and extent ofthe uptake of the compound by the worm. An integrated use of
transcriptomic, proteomic and metabolomic techniques (Mikami
et al., 2012; Schwarz et al., 2013; Preston et al., 2016c) might be
able to elucidate the physiological and biological pathways in
H. contortus and/or other worms affected by SN00797439.
The route from discovery to development and then to the
market of a new anthelmintic is a long one, requiring a serious
commitment in terms of time, effort and funding. In this present
study, we identiﬁed a new hit compound with activity against
biologically and genetically distinct nematodes. The novel and
rather unexplored chemical scaffold of the hit compound as well as
the observed broad activity make this compound a starting point
for designing and optimising new chemotherapeutics. Thus, we are
now eager to critically assess the activity of SN00797439 on key
developmental stages of a range of parasitic nematodes of humans,
including Ascaris sp. (large roundworm) and other common species
of hookworm (Necator americanus and Ancylostoma duodenale) as
well as additional ﬁlarial worms (Onchocerca volvulus and Loa Loa)
which cause some of the most neglected tropical diseases and
collectively affect ~ 1.8 billion people, resulting in a loss of 8.5
million DALYs worldwide (e.g., Hotez et al., 2016). Importantly,
substantial future work also needs to focus on (i) studying the
structure-activity relationship (SAR) of derivatives of compounds
SN00797439 via medicinal chemistry optimization, to attain a new
entity with broad-spectrum and enhanced activity against key
nematode stages; (ii) on assessing the pharmacological properties
(absorption, distribution, metabolism, excretion and toxicity;
ADMET) of the most promising compound series; and ultimately
(iii) on evaluating anthelmintic efﬁcacy and safety of active com-
pounds in vivo in animals.
Conﬂict of interest
There is no conﬂict of interest of any of the authors of this
manuscript.
Acknowledgements
The present study was funded by the National Health and
Medical Research Council of Australia (NHMRC), the Australian
Research Council (ARC) and the Wellcome Trust (RBG), and sup-
ported by a Victoria Life Sciences Computation Initiative, Australia
(VLSCI; grant no. VR0007) on its Peak Computing Facility at The
University of Melbourne, Australia, an initiative of the Victorian
Government, Australia. Animal ethics approval (AEC no. 0707258)
was granted by The University of Melbourne. We thank our col-
leagues at Medicines for Malaria Ventures (MMV) for their support.
We expressly wish to acknowledge the efforts of the constructors of
S. Preston et al. / International Journal for Parasitology: Drugs and Drug Resistance 7 (2017) 286e294294the 'Open Scaffold' library at Compounds Australia, David Camp,
Graeme Stevenson, Mikhail Krasavin and Alain-Dominique Gorse.
The Victorian Centre for Functional Genomics (KJS) is supported by
funding from the Australian Government's Education Investment
Fund through the Super Science Initiative and the Peter MacCallum
Cancer Centre Foundation. We thank an anonymous reviewer for
constructive comments and suggestions on our manuscript.
Appendix B. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.ijpddr.2017.05.004.
References
Baell, J.B., 2016. Feeling nature's PAINs: natural products, natural product drugs, and
pan assay interference compounds (PAINs). J. Nat. Prod. 79, 616e628.
Baell, J.B., Holloway, G.A., 2010. New substructure ﬁlters for removal of pan assay
interference compounds (PAINs) from screening libraries and for their exclu-
sion in bioassays. J. Med. Chem. 53, 2719e2740.
Campbell, W.C., 2016. Lessons from the history of ivermectin and other antiparasitic
agents. Annu. Rev. Anim. Biosci. 4, 1e14.
Cintra, M.C., Teixeira, V.N., Nascimento, L.V., Sotomaior, C.S., 2016. Lack of efﬁcacy of
monepantel against Trichostrongylus colubriformis in sheep in Brazil. Vet. Par-
asitol. 216, 4e6.
Fenwick, A., 2012. The global burden of neglected tropical diseases. Public Health
126, 233e236.
Fitzpatrick, J.L., 2013. Global food security: the impact of veterinary parasites and
parasitologists. Vet. Parasitol. 195, 233e248.
Foth, B.J., Tsai, I.J., Reid, A.J., Bancroft, A.J., Nichol, S., Tracey, A., Holroyd, N.,
Cotton, J.A., Stanley, E.J., Zarowiecki, M., Liu, J.Z., Huckvale, T., Cooper, P.J.,
Grencis, R.K., Berriman, M.L., 2014. Whipworm genome and dual-species
transcriptome analyses provide molecular insights into an intimate host-
parasite interaction. Nat. Genet. 46, 693e702.
Geary, T.G., Sakanari, J.A., Caffrey, C.R., 2015. Anthelmintic drug discovery: into the
future. J. Parasitol. 101, 125e133.
Harder, A., 2016. The biochemistry of Haemonchus contortus and other parasitic
nematodes. Adv. Parasitol. 93, 69e94.
Homer, R.W., Swanson, J., Jilek, R.J., Hurst, T., Clark, R.D., 2008. SYBYL line notation
(SLN): a single notation to represent chemical structures, queries, reactions, and
virtual libraries. J. Chem. Inf. Model 48, 2294e2307.
Hotez, P.J., Bottazzi, M.E., Strych, U., 2016. New vaccines for the world's poorest
people. Annu. Rev. Med. 67, 405e417.
Hotez, P.J., Alvarado, M., Basa~nez, M.G., Bolliger, I., Bourne, R., Boussinesq, M.,
Brooker, S.J., Brown, A.S., Buckle, G., Budke, C.M., Carabin, H., Coffeng, L.E.,
Fevre, E.M., Fürst, T., Halasa, Y.A., Jasrasaria, R., Johns, N.E., Keiser, J., King, C.H.,
Lozano, R., Murdoch, M.E., O'Hanlon, S., Pion, S.D.S., Pullan, R.L., Ramaiah, K.D.,
Roberts, T., Shepard, D.S., Smith, J.L., Stolk, W.A., Undurraga, E.A., Utzinger, J.,
Wang, M., Murray, C.J.L., Naghavi, M., 2014. The global burden of disease study
2010: interpretation and implications for the neglected tropical diseases. PLoS
Negl. Trop. Dis. 8, e2865.
Kaplan, R.M., Vidyashankar, A.N., 2012. An inconvenient truth: global worming and
anthelmintic resistance. Vet. Parasitol. 186, 70e78.
Kaminsky, R., Ducray, P., Jung, M., Clover, R., Rufener, L., Bouvier, J., Wenger, A.,
Schroeder, F., Desaules, Y., Hotz, R., Goebel, T., Hosking, B.C., Pautrat, F., Wieland-
Berghausen, S., Ducray, P., 2008. A new class of anthelmintics effective against
drug-resistant nematodes. Nature 452, 176e180.
Knox, M.R., Besier, R.B., Le Jambre, L.F., Kaplan, R.M., Torres-Acosta, J.F., Miller, J.,
Sutherland, J., 2012. Novel approaches for the control of helminth parasites of
livestock VI: summary of discussions and conclusions. Vet. Parasitol. 186,
143e149.
Kotze, A.C., Prichard, R.K., 2016. Anthelmintic resistance in Haemonchus contortus:
history, mechanisms and diagnosis. Adv. Parasitol. 93, 397e428.
Kumarasingha, R., Preston, S., Yeo, T.C., Lim, D.S.L., Tu, C.L., Palombo, E.A., Shaw, J.M.,
Gasser, R.B., Boag, P.R., 2016. Anthelmintic activity of selected ethno-medicinal
plant extracts on parasitic stages of Haemonchus contortus. Parasit. Vectors 9,
187.
Lane, J., Jubb, T., Shephard, R., Webb-Ware, J., Fordyce, G., 2015. MLA Final Report:
Priority List of Endemic Diseases for the Red Meat Industries. MLA. Available
from:. Accessed 7th September 2016. www.mla.com.au/download/ﬁnalreports?itemId¼2877.
Li, L., Zhong, M., 2011. Preparation of Biarylacetylenes, Arheteroarylacetylenes and
Biheteroarylacetylenes End-capped with Amino Acid or Peptide Derivatives as
Inhibitors of HCV NS5A. Patent WO 2011150243 A1 20111201.
Li, L., Zhong, M., 2010. Preparation of Biarylacetylenes, Arheteroarylacetylenes and
Biheteroarylacetylenes End-capped with Amino Acid or Peptide Derivatives as
IInhibitors of HCV NS5A. Patent WO 2010065668 A1 20100610.
Little, P.R., Hodge, A., Maeder, S.J., Wirtherle, N.C., Nicholas, D.R., Cox, G.G.,
Conder, G.A., 2011. Efﬁcacy of a combined oral formulation of derquan-
teleabamectin against the adult and larval stages of nematodes in sheep,
including anthelmintic-resistant strains. Vet. Parasitol. 181, 180e193.
Martin, R.J., Buxton, S.K., Neveu, C., Charvet, C.L., Robertson, A.P., 2012. Emodepside
and SL0-1 potassium channels: a review. Exp. Parasitol. 132, 40e46.
Michalski, M.L., Grifﬁths, K.G., Williams, S.A., Kaplan, R.M., Moorhead, A.R., 2011.
The NIH-NIAID ﬁlariasis research reagent resource center. PLoS Negl. Trop. Dis.
5, e1261.
Mikami, T., Aoki, M., Kimura, T., 2012. The application of mass spectrometry to
proteomics and metabolomics in biomarker discovery and drug development.
Curr. Mol. Pharmacol. 5, 301e316.
Mutafchiev, Y., Bain, O., Williams, Z., McCall, J.W., Michalski, M.L., 2014. Intraperi-
toneal development of the ﬁlarial nematode Brugia malayi in the Mongolian jird
(Meriones unguiculatus). Parasitol. Res. 113, 1827e18235.
Preston, S., Jabbar, A., Gasser, R.B., 2016a. A perspective on genomic-guided
anthelmintic discovery and repurposing using Haemonchus contortus. Infect.
Genet. Evol. 40, 368e373.
Preston, S., Jabbar, A., Nowell, C., Joachim, A., Ruttkowski, B., Baell, J., Cardno, T.,
Korhonen, P.K., Piedraﬁta, D., Ansell, B.R., Jex, A.R., Hofmann, A., Gasser, R.B.,
2015. Low cost whole-organism screening of compounds for anthelmintic ac-
tivity. Int. J. Parasitol. 45, 333e343.
Preston, S., Jabbar, A., Nowell, C., Joachim, A., Ruttkowski, B., Cardno, T., Hofmann, A.,
Gasser, R.B., 2016b. Practical and low cost whole-organism motility assay: a
step-by-step protocol. Mol. Cell. Probes 30, 13e17.
Preston, S., Luo, J., Zhang, Y., Jabbar, A., Crawford, S., Baell, J., Hofmann, A., Hu, M.,
Zhou, H.B., Gasser, R.B., 2016c. Selenophene and thiophene-core estrogen re-
ceptor ligands that inhibit motility and development of parasitic stages of
Haemonchus contortus. Parasit. Vectors 9, 346.
Prichard, R.K., Geary, T.G., 2008. Drug discovery: fresh hope to can the worms.
Nature 452, 157e158.
Roeber, F., Jex, A.R., Gasser, R.B., 2013. Impact of gastrointestinal parasitic nema-
todes of sheep, and the role of advanced molecular tools for exploring epide-
miology and drug resistance - an Australian perspective. Parasit. Vectors 6, 153.
Sales, N., Love, S., 2016. Resistance of Haemonchus sp. to monepantel and reduced
efﬁcacy of a derquantel abamectin combination conﬁrmed in sheep in NSW,
Australia. Vet. Parasitol. 15, 193e196.
Schwarz, E.M., Korhonen, P.K., Campbell, B.E., Young, N.D., Jex, A.R., Jabbar, A.,
Hall, R.S., Mondal, A., Howe, A.C., Pell, J., Hofmann, A., Boag, P.R., Zhu, X.Q.,
Gregory, T., Loukas, A., Williams, B.A., Antoshechkin, I., Brown, C.,
Sternberg, P.W., Gasser, R.B., 2013. The genome and developmental tran-
scriptome of the strongylid nematode Haemonchus contortus. Genome Biol. 14,
R89.
Scott, I., Pomroy, W.E., Kenyon, P.R., Smith, G., Adlington, B., Moss, A., 2013. Lack of
efﬁcacy of monepantel against Teladorsagia circumcincta and Trichostrongylus
colubriformis. Vet. Parasitol. 198, 166e171.
Simpson, M., Poulsen, S.A., 2014. An overview of Australia's compound manage-
ment facility: the Queensland Compound Library. ACS Chem. Biol. 9, 28e33.
Sommerville, R.I., 1966. The development of Haemonchus contortus to the fourth
stage in vitro. J. Parasitol. 52, 127e136.
Steinmann, P., Zhou, X.N., Du, Z.W., Jiang, J.Y., Xiao, S.H., Wu, Z.X., Zhou, H.,
Utzinger, J., 2008. Tribendimidine and albendazole for treating soil-transmitted
helminths, Strongyloides stercoralis and Taenia spp.: open-label randomized
trial. PLoS Negl. Trop. Dis. 2, e322.
Storey, B., Marcellino, C., Miller, M., Maclean, M., Mostafa, E., Howell, S., Sakanari, J.,
Wolstenholme, A., Kaplan, R., 2014. Utilization of computer processed high
deﬁnition video imaging for measuring motility of microscopic nematode
stages on a quantitative scale: “The Worminator”. Int. J. Parasitol. Drugs Drug
Resist 4, 233e243.
Van den Brom, R., Moll, L., Kappert, C., Vellema, P., 2015. Haemonchus contortus
resistance to monepantel in sheep. Vet. Parasitol. 209, 278e280.
Wolstenholme, A.J., Kaplan, R.M., 2012. Resistance to macrocyclic lactones. Curr.
Pharm. Biotechnol. 13, 873e887.
Xiao, S.H., Hui-Ming, W., Tanner, M., Utzinger, J., Chong, W., 2005. Tribendimidine: a
promising, safe and broad-spectrum anthelmintic agent from China. Acta Trop.
94, 1e14.
